MAPT and Alzheimer disease: Subjects with no clinical symptoms of AD but who have a parental history of AD or possess a risk gene for AD, the ε4 allele of apolipoprotein E (APOE ε4) or positive CSF tau/Aβ42 biomarkers, are also considered preclinical AD.42